Literature DB >> 28859336

Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.

Andrew M Donson1, John Apps1, Andrea M Griesinger1, Vladimir Amani1, Davis A Witt1, Richard C E Anderson1, Toba N Niazi1, Gerald Grant1, Mark Souweidane1, James M Johnston1, Eric M Jackson1, Bette K Kleinschmidt-DeMasters1, Michael H Handler1, Aik-Choon Tan1, Lia Gore1, Alex Virasami1, Jose Mario Gonzalez-Meljem1, Thomas S Jacques1, Juan Pedro Martinez-Barbera1, Nicholas K Foreman1, Todd C Hankinson1.   

Abstract

Pediatric adamantinomatous craniopharyngioma (ACP) is a highly solid and cystic tumor, often causing substantial damage to critical neuroendocrine structures such as the hypothalamus, pituitary gland, and optic apparatus. Paracrine signaling mechanisms driving tumor behavior have been hypothesized, with IL-6R overexpression identified as a potential therapeutic target. To identify potential novel therapies, we characterized inflammatory and immunomodulatory factors in ACP cyst fluid and solid tumor components. Cytometric bead analysis revealed a highly pro-inflammatory cytokine pattern in fluid from ACP compared to fluids from another cystic pediatric brain tumor, pilocytic astrocytoma. Cytokines and chemokines with particularly elevated concentrations in ACPs were IL-6, CXCL1 (GRO), CXCL8 (IL-8) and the immunosuppressive cytokine IL-10. These data were concordant with solid tumor compartment transcriptomic data from a larger cohort of ACPs, other pediatric brain tumors and normal brain. The majority of receptors for these cytokines and chemokines were also over-expressed in ACPs. In addition to IL-10, the established immunosuppressive factor IDO-1 was overexpressed by ACPs at the mRNA and protein levels. These data indicate that ACP cyst fluids and solid tumor components are characterized by an inflammatory cytokine and chemokine expression pattern. Further study regarding selective cytokine blockade may inform novel therapeutic interventions.
© 2017 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Adamantinomatous craniopharyngioma; Craniopharyngioma cyst; Cytokine; IL-6; Immunomodulation; Inflammatory

Mesh:

Substances:

Year:  2017        PMID: 28859336      PMCID: PMC6005018          DOI: 10.1093/jnen/nlx061

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  51 in total

1.  Localization of indoleamine 2,3-dioxygenase in human female reproductive organs and the placenta.

Authors:  P Sedlmayr; A Blaschitz; R Wintersteiger; M Semlitsch; A Hammer; C R MacKenzie; W Walcher; O Reich; O Takikawa; G Dohr
Journal:  Mol Hum Reprod       Date:  2002-04       Impact factor: 4.025

2.  Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.

Authors:  Andrea M Griesinger; Rebecca J Josephson; Andrew M Donson; Jean M Mulcahy Levy; Vladimir Amani; Diane K Birks; Lindsey M Hoffman; Steffanie L Furtek; Phillip Reigan; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman
Journal:  Cancer Immunol Res       Date:  2015-05-12       Impact factor: 11.151

3.  Insights into the infiltrative behavior of adamantinomatous craniopharyngioma in a new xenotransplant mouse model.

Authors:  Christina Stache; Annett Hölsken; Sven-Martin Schlaffer; Andreas Hess; Markus Metzler; Benjamin Frey; Rudolf Fahlbusch; Jörg Flitsch; Michael Buchfelder; Rolf Buslei
Journal:  Brain Pathol       Date:  2014-05-19       Impact factor: 6.508

4.  Analysis of mouse models carrying the I26T and R160C substitutions in the transcriptional repressor HESX1 as models for septo-optic dysplasia and hypopituitarism.

Authors:  Ezat Sajedi; Carles Gaston-Massuet; Massimo Signore; Cynthia L Andoniadou; Daniel Kelberman; Sandra Castro; Heather C Etchevers; Dianne Gerrelli; Mehul T Dattani; Juan Pedro Martinez-Barbera
Journal:  Dis Model Mech       Date:  2008-11-06       Impact factor: 5.758

5.  Expression of interleukin-6 in human craniopharyngiomas: a possible inducer of tumor-associated inflammation.

Authors:  Masanao Mori; Hideo Takeshima; Jun-ichi Kuratsu
Journal:  Int J Mol Med       Date:  2004-10       Impact factor: 4.101

6.  Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans.

Authors:  Carles Gaston-Massuet; Cynthia Lilian Andoniadou; Massimo Signore; Sujatha A Jayakody; Nicoletta Charolidi; Roger Kyeyune; Bertrand Vernay; Thomas S Jacques; Makoto Mark Taketo; Paul Le Tissier; Mehul T Dattani; Juan Pedro Martinez-Barbera
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-02       Impact factor: 11.205

7.  Sox2(+) stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential.

Authors:  Cynthia Lilian Andoniadou; Danielle Matsushima; Seyedeh Neda Mousavy Gharavy; Massimo Signore; Albert Ian Mackintosh; Marie Schaeffer; Carles Gaston-Massuet; Patrice Mollard; Thomas Stanley Jacques; Paul Le Tissier; Mehul Tulsidas Dattani; Larysa Halyna Pevny; Juan Pedro Martinez-Barbera
Journal:  Cell Stem Cell       Date:  2013-10-03       Impact factor: 24.633

8.  Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.

Authors:  Cynthia L Andoniadou; Carles Gaston-Massuet; Rukmini Reddy; Ralph P Schneider; Maria A Blasco; Paul Le Tissier; Thomas S Jacques; Larysa H Pevny; Mehul T Dattani; Juan Pedro Martinez-Barbera
Journal:  Acta Neuropathol       Date:  2012-02-18       Impact factor: 17.088

9.  Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.

Authors:  Priscilla K Brastianos; Amaro Taylor-Weiner; Peter E Manley; Robert T Jones; Dora Dias-Santagata; Aaron R Thorner; Michael S Lawrence; Fausto J Rodriguez; Lindsay A Bernardo; Laura Schubert; Ashwini Sunkavalli; Nick Shillingford; Monica L Calicchio; Hart G W Lidov; Hala Taha; Maria Martinez-Lage; Mariarita Santi; Phillip B Storm; John Y K Lee; James N Palmer; Nithin D Adappa; R Michael Scott; Ian F Dunn; Edward R Laws; Chip Stewart; Keith L Ligon; Mai P Hoang; Paul Van Hummelen; William C Hahn; David N Louis; Adam C Resnick; Mark W Kieran; Gad Getz; Sandro Santagata
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 38.330

10.  Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma.

Authors:  Hsiao-Yun Chen; Liang-Ting Lin; Mong-Lien Wang; Shu-Hsien Lee; Ming-Long Tsai; Chi-Chang Tsai; Wei-Hsiu Liu; Tzu-Chien Chen; Yi-Ping Yang; Yi-Yen Lee; Yuh-Lih Chang; Pin-I Huang; Yi-Wei Chen; Wen-Liang Lo; Shih-Hwa Chiou; Ming-Teh Chen
Journal:  Oncotarget       Date:  2016-07-05
View more
  22 in total

1.  Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma.

Authors:  Andrew M Donson; Vladimir Amani; Elliot A Warner; Andrea M Griesinger; Davis A Witt; Jean M Mulcahy Levy; Lindsey M Hoffman; Todd C Hankinson; Michael H Handler; Rajeev Vibhakar; Kathleen Dorris; Nicholas K Foreman
Journal:  Mol Cancer Ther       Date:  2018-06-20       Impact factor: 6.261

2.  Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.

Authors:  Shannon Coy; Rumana Rashid; Jia-Ren Lin; Ziming Du; Andrew M Donson; Todd C Hankinson; Nicholas K Foreman; Peter E Manley; Mark W Kieran; David A Reardon; Peter K Sorger; Sandro Santagata
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

Review 3.  Adamantinomatous craniopharyngioma: advances in proteomic research.

Authors:  Claudia Desiderio; Diana Valeria Rossetti; Massimo Castagnola; Luca Massimi; Gianpiero Tamburrini
Journal:  Childs Nerv Syst       Date:  2020-07-02       Impact factor: 1.475

4.  Prediction of calcification tendency in pediatric cystic adamantinomatous craniopharyngioma by using inflammatory markers, hormone markers, and radiological appearances.

Authors:  Ming Chen; Zhang Zhang; Min Yang; Shi-Ting Li
Journal:  Childs Nerv Syst       Date:  2019-05-07       Impact factor: 1.475

Review 5.  Hypothalamic syndrome.

Authors:  Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen
Journal:  Nat Rev Dis Primers       Date:  2022-04-21       Impact factor: 52.329

6.  Treatment of Cystic Craniopharyngiomas: An Update.

Authors:  Federico Bianchi; Alberto Benato; Luca Massimi
Journal:  Adv Tech Stand Neurosurg       Date:  2022

7.  The diagnostic value of preoperative inflammatory markers in craniopharyngioma: a multicenter cohort study.

Authors:  Ming Chen; Shi-Hao Zheng; Min Yang; Zhi-Hua Chen; Shi-Ting Li
Journal:  J Neurooncol       Date:  2018-01-31       Impact factor: 4.130

Review 8.  Craniopharyngioma adherence: a reappraisal of the evidence.

Authors:  Ruth Prieto; José María Pascual; Verena Hofecker; Eduard Winter; Inés Castro-Dufourny; Rodrigo Carrasco; Laura Barrios
Journal:  Neurosurg Rev       Date:  2018-07-24       Impact factor: 3.042

9.  Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.

Authors:  Jichang Han; Meng Yu; Yiqin Bai; Jianzhong Yu; Fei Jin; Chen Li; Rong Zeng; Jinghong Peng; Ao Li; Xiaomin Song; Hao Li; Dianqing Wu; Lin Li
Journal:  Cancer Cell       Date:  2020-11-12       Impact factor: 31.743

Review 10.  Medical Therapy for Craniopharyngiomas.

Authors:  Krystallenia I Alexandraki; Paraskevi Xekouki
Journal:  touchREV Endocrinol       Date:  2021-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.